Benign Conditions

A minimally invasive implant procedure led to a 50% improvement in lower urinary tract symptoms due to BPH, which was maintained for a year, results of a randomized trial showed.

An analysis of data from three studies that involved a total of more than 240,000 participants found that a self-reported history of kidney stones was associated with a statistically significant increased risk of coronary heart disease among women.

Drugs and devices in the pipeline from Targacept, Inc., Cubist, OncoGenex Pharmaceuticals, Inc., Apricus Biosciences, and Nymox Pharmaceutical Corp.

New products and services from GenomeDx Biosciences, the Coding Institute, Astellas Pharma US, Greenbranch Publishing, the National Association for Continence, Perrigo Co., the Bladder Cancer Advocacy Network, and the Brewer Co.

Bruce R. Kava, MD, presents the take home messages on BPH/LUTS from the AUA annual meeting in San Diego.

Mantu Gupta, MD, presents the take home messages on stone disease/endourology from the AUA annual meeting in San Diego.

Priya Padmanabhan, MD, MPH, presents the take home messages on female urology/incontinence/urodynamics from the AUA annual meeting in San Diego.

Danil V. Makarov, MD, MHS, presents the take home messages on outcomes analysis.

Jeannette M. Potts, MD, presents the take home messages on infection and inflammation at the AUA annual meeting in San Diego.

Estrogen supplements may help menopausal women ward off recurrent urinary tract infections, researchers recently reported.

A generic version of the overactive bladder drug trospium chloride has received FDA approval and is now available.

Consumption of sugar-sweetened soda and punch is associated with an elevated risk of kidney stone formation, according to a recent study.

The new-generation GreenLight XPS-180W laser system (American Medical Systems, Minnetonka, MN) achieved an improved rate of tissue vaporization and overall efficacy in patients with BPH compared to an earlier generation laser, according to results of a recent multicenter study.

In this case, the woman claimed her damages from the negligent nerve injury included pain and weakness in her legs and a second operation to replace the sling.

Data from a recent multicenter study provide new evidence that the beta-3 adrenoceptor agonist mirabegron (Myrbetriq) appears to be a viable alternative in patients with overactive bladder (OAB) who are poor responders to antimuscarinic agents or intolerant of their adverse events.

Men with symptomatic BPH had statistically significant, durable improvement in lower urinary tract symptoms (LUTS) following an office-based, minimally invasive prostatic urethral lift procedure, results of a pivotal randomized trial showed.

Stress incontinent women whose urinary urgency incontinence worsens following a sling procedure are a heterogeneous group, researchers report.

Mesh removal after suburethral sling procedures led to additional incontinence surgery in more than half of patients, including many who were continent prior to sling removal, a study of almost 100 patients showed.

Postmenopausal women may reduce their risk of incident kidney stone disease by engaging in physical activity and avoiding excessive caloric intake, analyses of data collected in the Women’s Health Initiative Observational Study show.

With rates of stone disease on the rise in the U.S., researchers have turned their attention to possible causes. New research exploring the possible influence of diabetes, diet, and even being a surgeon will be presented at the upcoming AUA annual meeting.

In the area of female urology, look for key studies at the AUA annual meeting involving sling surgery, onabotulinumtoxinA (Botox) injections, and reoperation after pelvic organ prolapse surgery with mesh.

Data from a recent multicenter study provide new evidence that the beta-3 adrenoceptor agonist mirabegron (Myrbetriq) appears to be a viable alternative in patients with overactive bladder who are poor responders to antimuscarinic agents or intolerant of their adverse events.

THVD-201 (Tolenix), a novel formulation combining tolterodine and pilocarpine, was found safe, well tolerated, and effective against overactive bladder (OAB) in a recent study.

The algorithm for urologists’ approach to male voiding symptoms is evolving, according to Steven A. Kaplan, MD, of Weill Cornell Medical College, New York. This will be evident in presentations on BPH and lower urinary tract symptoms at the AUA annual meeting.

As in adult urology, minimally invasive approaches continue to grow in pediatric urology, which is reflected in the research being presented at this year’s AUA annual meeting.